Pulling SEC filings + quote and writing the call…
Pulling SEC filings + quote and writing the call…
Fulcrum Therapeutics, Inc.
Next earnings ≈ Jul 27, 2026 · est. from filing cadence
Last earnings -1.5% on 2026-04-27
Conservative balance sheet (liabilities/equity 0.05x); but revenue fell -100.0% YoY.
Rules-based read computed from SEC figures — no Anthropic key set. Add ANTHROPIC_API_KEY to .env.local for a full Claude analysis.
Fulcrum Therapeutics, Inc. shows $0.00 in FY2025 revenue (-100.0% YoY), and -21.5% ROE.
The risks, catalysts, 12-month price target and the cited SEC figures behind this rating — with Pro.
Unlock with Pro€15/mo · cancel anytime
Sources: SEC EDGAR (CIK 0001680581, latest 10-Q filed 2026-04-27) · EODHD · rules-based read · as of 6/18/2026, 10:35:23 AM.
Research and education only — not financial advice. Calls are generated from SEC filings and a delayed/third-party price feed, may be wrong or out of date, and are not a recommendation to buy or sell any security. Do your own research.
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | $19.2M | $6.34M | $2.81M | $80.0M | $0.00 |
| Gross profit | — | — | — | — | — |
| Operating income | -$81.1M | -$113M | -$111M | -$21.9M | -$84.8M |
| Net income | -$80.8M | -$110M | -$97.3M | -$9.72M | -$74.9M |
| Diluted EPS | -$2.29 | -$2.44 | -$1.59 | -$0.16 | -$1.18 |
| Net margin | -421.9% | -1732.4% | -3470.1% | -12.2% | — |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
501 tracked peers · median
| 2026-02-02 | Gould Robert J Director | Sell | 15.0K @ $10.72 | $161K |
| 2026-01-02 | Gould Robert J Director | Sell | 15.0K @ $11.87 | $178K |
| 2025-12-15 | Oltmans Curtis Gale Chief Legal Officer | Sell | 3.45K @ $12.92 | $44.6K |